Join

Compare · ARGX vs BCAB

ARGX vs BCAB

Side-by-side comparison of argenx SE (ARGX) and BioAtla Inc. (BCAB): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ARGX and BCAB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • ARGX is the larger of the two at $63.27B, about 11649.2x BCAB ($5.4M).
  • ARGX has been more active in the news (12 items in the past 4 weeks vs 1 for BCAB).
  • ARGX has more recent analyst coverage (25 ratings vs 8 for BCAB).
MetricARGXBCAB
Company
argenx SE
BioAtla Inc.
Price
$1042.40+2.23%
$3.33+1.83%
Market cap
$63.27B
$5.4M
1M return
-
-1.48%
1Y return
-
-83.74%
Sector
Health Care
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2017
2020
News (4w)
12
1
Recent ratings
25
8
ARGX

argenx SE

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

BCAB

BioAtla Inc.

BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.

Latest ARGX

Latest BCAB